In this article, we will list the 5 Most Promising Healthcare Stocks According to Wall Street Analysts. Please visit 10 Most Promising Healthcare Stocks According to Wall Street Analysts if you would like to see the extended list and the methodology behind it.

5. Cogent Biosciences, Inc. (NASDAQ:COGT)

Stock Upside: 68.25%

Market Capitalization: $5.55 billion

Number of Hedge Fund Holders: 77

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 12, Cogent Biosciences, Inc. (NASDAQ:COGT) presented early-stage preclinical data for its experimental drug CGT1145 at the European Hematology Association Congress in Stockholm, Sweden. The company presented the drug candidate as a potentially more precise and better-tolerated treatment for certain rare blood cancers compared to what is currently available.

The lab results showed that CGT1145 was more than 100-fold selective for JAK2 V617F over wild-type JAK2 and JAK1/3 isoforms. JAK2 V617F is a gene mutation associated with blood cancers like myelofibrosis, polycythemia vera, and essential thrombocythemia. Cogent designed CGT1145 which is a mutant-selective JAK2 inhibitor. Other treatments in the market can do that, but unlike CGT1145, they cause side effects like low blood counts because they hit both the mutated and normal versions of the gene.

The data also suggested that CGT1145 may be able to eliminate the cells that drive the rare blood cancers at a root level. As a result, it may have the potential to support molecular remission. The drug also showed strong oral bioavailability, meaning it absorbs well when taken as a pill. It also behaves consistently across different biological systems tested.

Because of the robust results, Andrew Robbins, Cogent’s President and CEO said that the company is on track to file an Investigational New Drug application with the FDA later this year.

Cogent Biosciences, Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined cancers. Its lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor targeting KIT mutations.

4. Legend Biotech Corporation (NASDAQ:LEGN)

Stock Upside: 78.73%

Market Capitalization: $6.24 billion

Number of Hedge Fund Holders: 31

Legend Biotech Corporation (NASDAQ:LEGN) is one of the most promising healthcare stocks according to Wall Street analysts. Legend Biotech Corporation (NASDAQ:LEGN) recently announced the first human proof-of-concept results for LB2501, its experimental next-generation cancer therapy. The company presented the data at the European Hematology Association 2026 Congress.

Legend said LB2501 is designed for patients with B-cell non-Hodgkin lymphoma, a blood cancer affecting white blood cells. It added that LB2501 is different from existing cell therapies because rather than removing a patient’s immune cells, engineering them in a laboratory, and reinfusing them, the treatment delivers genetic instructions directly into the patient’s body via a single intravenous infusion.

The ongoing Phase 1 trial tested two dose levels with six patients each. Data showed that at the lower dose, results were modest, but at the higher dose, all six patients responded and five of them achieved a complete response. The data also showed no serious adverse events or treatment-related deaths reported at the data cutoff, though about two-thirds of patients did experience cytokine release syndrome. This is an immune overreaction that is common with this class of therapy, the company said.

Legend also noted that the modified virus used to deliver the genetic instructions was no longer detected in circulation within 24 hours of infusion. It also left a highly diverse, polyclonal integration pattern, which in plain terms means the reprogramming happened in a broad, distributed way rather than concentrating in specific cells.

Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage cell-therapy company. It specializes in the discovery and development of novel cell therapies for oncology and other indications.

3. Insmed Incorporated (NASDAQ:INSM)

Stock Upside: 111.74%

Market Capitalization: $20.44 billion

Number of Hedge Fund Holders: 67

Insmed Incorporated (NASDAQ:INSM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Cantor Fitzgerald reaffirmed its Overweight rating on Insmed Incorporated (NASDAQ:INSM) and raised its price target from $230 to $235.

The firm pointed to an upcoming data release for Insmed’s experimental lung drug TPIP as a potential catalyst that investors may be underestimating. TPIP, which stands for Treprostinil Palmitil Inhalation Powder, is an inhaled therapy Insmed is developing for pulmonary arterial hypertension (PAH).

According to Cantor Fitzgerald, it has been roughly a year since Insmed first presented the Phase 2b clinical trial results for TPIP in PAH. The firm sees the next data release as a moment that could meaningfully revive investor interest in the drug. This data is a one-year open label extension update expected in Q3 2026. For context, an open label extension is the phase of a clinical study where all patients are given the actual drug and monitored over a longer period, and the data from this phase typically gives a clearer picture of how durable and safe the treatment is over time.

The firm noted that if the next data release provides robust results, the market may shift focus from Brinsupri, Insmed’s drug for non-cystic fibrosis bronchiectasis. This is because the market is significantly undervaluing TPIP just because Brinsupri posted blowout revenue at the end of Q1 2026.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company. It focuses on developing and commercializing therapies for serious and rare diseases. One of its lead approved product is ARIKAYCE, an inhaled antibiotic delivered via the Lamira Nebulizer System.

2. Vaxcyte, Inc. (NASDAQ:PCVX)

Stock Upside: 123.85%

Market Capitalization: $7.09 billion

Number of Hedge Fund Holders: 57

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. VAX-A1 is the company’s experimental vaccine against Group A Streptococcus, or Group A Strep.

The dosing marks Vaxcyte’s entry of what would be the first-in-human vaccine candidate for Group A Strep, a disease for which no approved vaccine currently exists. For context, Vaxcyte estimates that Group A Strep is responsible for 800 million illnesses globally every year, and the illnesses range from common strep throat to severe, life-threatening infections and long-term complications like rheumatic heart disease. Despite this burden, no approved vaccine exists anywhere in the world, noted Vaxcyte.

For the trial, Vaxcyte will enroll 80 healthy adults aged 18 to 40 in Australia. The company said the choice of Australia is because the country has high rates of Group A Strep disease. It also has established research networks with deep expertise in studying it. Vaxcyte will structure the study in two stages, where Stage 1 will include 12 participants who will serve as a safety checkpoint before an independent safety board reviews results and approves the expansion to Stage 2.

All participants will receive two doses of VAX-A1 or a placebo, which will be spaced about two months apart. They will then be monitored for six months after the final dose. The trial will test low, mid, and high dose levels to find the right balance between immune response and tolerability.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company.

1. Summit Therapeutics Inc. (NASDAQ:SMMT)

Stock Upside: 129.89%

Market Capitalization: $10.82 billion

Number of Hedge Fund Holders: 34

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Summit Therapeutics Inc. (NASDAQ:SMMT) withdrew a $500 million proposed underwritten public offering it had announced just one day earlier. The company cited unfavorable market conditions.

The plan was to use the proceeds to fund ongoing research and development of ivonescimab, the company’s lead drug. Ivonescimab is a bispecific antibody that simultaneously targets the two proteins on which cancer cells rely to grow and hide from the immune system. The drug is currently the most closely watched asset in Summit’s pipeline and is already approved in China.

Summit had proposed the offering just nine days after its Chinese partner Akeso presented Phase 3 data from a China-based lung cancer trial of ivonescimab. The results showed a 34% reduction in the risk of death compared to a competing therapy. However, a CNBC report raised the concern that the data may not be as useful to Summit because the trial was conducted in China.

CNBC quoted Dr. Suresh Ramalingam, executive director of the Winship Cancer Institute of Emory University, who said: “I’m mindful of the fact that this trial was done exclusively in China, and that brings up the question of how do these data apply to patient populations outside of China, and that will require future investigations.”

Dr. Ramalingam explained that their concerns are not that the drug doesn’t work. In fact, he called the results good news for Chinese patients. Instead, their concern is that one can’t assume results from a China-only trial will translate to US or global patients, especially when there are biological reasons to expect the response to be different.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a clinical-stage biopharmaceutical company. Its lead candidate, ivonescimab, is a novel bispecific antibody targeting both PD-1 and VEGF pathways, and is currently being evaluated in multiple Phase 3 trials for non-small cell lung cancer and other solid tumors.

READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.